医学
脂联素
血糖性
嗜酸乳杆菌
益生菌
安慰剂
果糖胺
内科学
双歧杆菌
胃肠病学
抵抗素
2型糖尿病
随机对照试验
双歧杆菌
糖尿病
乳酸菌
内分泌学
胰岛素
发酵
胰岛素抵抗
食品科学
生物
细菌
替代医学
病理
遗传学
作者
Hércia Stampini Duarte Martino,Lívia Bordalo Tonucci,K. M. O. dos Santos,Leandro Licursi de Oliveira,Sonia M.R. Ribeiro
标识
DOI:10.1096/fasebj.29.1_supplement.922.6
摘要
Aims The aim of this clinical trial was to investigate the effects of probiotics on glycemic control and inflammatory and anti‐inflammatory markers in T2D. Methods In a double‐blind, randomized controlled trial, 50 subjects with T2D were assigned to two groups: probiotic group, consumed 120 g/d of fermented milk containing Lactobacillus acidophilus LA5 and Bifidobacterium lactis BB12 or placebo group, consumed 120 g/d of conventional fermented milk for 6 weeks. Anthropometric measurements, body composition and fasting blood were took at baseline and after 6 weeks intervention. Results The study demonstrated a significant decrease in fructosamine levels (p = 0.05) and haemoglobin A 1 c (HbA 1c ) tended to be lower (p = 0.07) in probiotic group. TNF‐ α and resistin were significantly reduced (p < 0.05) in both groups after end of trial, while IL‐10 was significantly reduced (p < 0.001) and adiponectin levels tended to be lower (p = 0.07) in the placebo group. There was a significant difference in mean changes of HbA1c, between groups (p < 0.05). No significant changes from baseline were shown in IL‐6 levels. Conclusion Probiotic consumption improved the glycemic control and prevented a reduction in anti‐inflamatory cytokines in T2D subjects. The Fermented milk intake seems to be involved with reductions in inflammatory markers. Research Support: Brazilian Foundation CAPES and CNPq
科研通智能强力驱动
Strongly Powered by AbleSci AI